Status:
UNKNOWN
Glypican-1 Expression in Epithelioid Mesothelioma, Adenocarcinoma and SCC of the Lung
Lead Sponsor:
Sohag University
Conditions:
Lung Cancer Adenocarcinoma
Lung Cancer Squamous Cell
Eligibility:
All Genders
Brief Summary
Lung carcinoma is the second most common cancer and a leading cause of cancer-related mortality worldwide. In Egypt, lung carcinoma ranks the 5th among all cancer cases. Malignant mesothelioma is an a...
Detailed Description
Lung carcinoma is the second most common cancer and a leading cause of cancer-related mortality worldwide, comprising almost 20% of all cancer deaths. In Egypt, lung carcinoma ranks the 5th among all ...
Eligibility Criteria
Inclusion
- Patients with pleural epithelioid mesothelioma and lung adenocarcinoma and SCC who underwent surgery
Exclusion
- Patients received pre-operative chemotherapy or radiotherapy.
- Patients with insufficient clinical data.
- Specimens with extensive necrosis
- Tiny specimens which are insufficient for accurate diagnosis.
Key Trial Info
Start Date :
February 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05228795
Start Date
February 1 2022
End Date
December 1 2022
Last Update
February 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Medicine, Sohag University
Sohag, Egypt